Discovering new drugs is both our profession and our passion.

Ecrins Therapeutics is a privately held biotech company specialized in the discovery and development of innovative oncology drugs for human and veterinary applications.

Discover our work and our team through this website

Backed by our skills and knowledge in this field, our commercial division, “Ecrins Therapeutics Products and Services”, aims to share our unique expertise in cytoskeleton characterisation with fellow scientists. To discover what we can do for you, please visit the Product & Services page and the dedicated website. We are certified “Research Tax Credit” (CIR- “Crédit d’Impôt Recherche”) for 2015-19 (see news).


May, 30th, 2016

Ecrins Therapeutics at the ASCO Meeting in Chicago.
From June 3rd to June 7th, Ecrins Therapeutics will be present at the ASCO Annual Meeting, held in Chicago.

March, 17th, 2016

Ecrins Therapeutics presents you its new website

December, 18th, 2015

Recent IP portfolio developments in Asia
Ecrins Therapeutics announces that the JPO (Japanese Patent Office) granted the patent N° 5 856 086.

July, 1st, 2015

Kickoff of the FUI project “Dog-to-Man”
Development of an innovative product for treating sarcomas: A Translational study from dog to man.

Welcome to Ecrins Therapeutics

But, why “Ecrins”? The Ecrins national park is a gorgeous part of the French Alps in which each hike become a fantastic adventure in front of amazing landscapes. Andrei Popov (one of the co-founder and our CEO) enjoys hiking and rock climbing in the Ecrins national park and none of us is insensitive to the beauty of mountains surrounding Grenoble.

Furthermore, we often see our work like a long trek to a summit, in which teamwork and perseverance are the keys to reaching our goals.

 The picture at the top of this page shows the “glacier blanc” (white glacier) and “La Barre des Ecrins”.